Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: Multicentre cohort study: The United Kingdom Collaborative HIV Cohort (CHIC) Study

AIDS

Volumn 22, Issue 15, 2008, Pages 1943-1950

  Sabin, Caroline A ^a   Lee, Katherine J ^b   Dunn, David ^b   Porter, Kholoud ^b   Bansi, Richard Gilson Loveleen ^a   Hill, Teresa ^a   Phillips, Andrew N ^a   Schwenk, Achim ^c   Leen, Clifford ^d   Delpech, Valerie ^e   Anderson, Jane ^f   Gazzard, Brian ^g   Johnson, Margaret ^h   Easterbrook, Philippa ⁱ   Walsh, John ^j   Fisher, Martin ^k   Orkin, Chloe ^l  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^h ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^k UK   (United Kingdom)

^l ROYAL LONDON HOSPITAL   (United Kingdom)

more..

Author keywords

Clinical practice; Guidelines; Highly active antiretroviral therapy; HIV; Treatment switching; Viral load rebound

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REBOUND; UNITED KINGDOM; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; VIRAL LOAD;

EID: 53549091856     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830e4cf3     Document Type: Article

References (31)

1. The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
2. Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a muiticenter cohort study. J Infect Dis 2005; 192:1387-1397.
3. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732.
4. Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antiviral Ther 2006; 11:553-560.
5. Goetz MB, Ferguson MR, Han X, McMillan G, St. Clair M, Pappa KA, et al. Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr 2006; 43:541-549.
6. Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E, et al. The effect of HI V-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Antiviral Ther 2006; 11:923-929.
7. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
8. Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, et al. What is the risk of mortality following diagnosis of multidrug resistant HIV-1 ? J Antimicrob Chemother 2008; 61:705-713.
9. Gazzard B, and BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2006; 7:487-503.
10. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection. 2006 Recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296:827-843.
11. Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antirelroviral-naïve patients. HIV Med 2007; 8:186-191.
12. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
13. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993; 12:737-751.
14. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18:681-694.
15. The UK Collaborative HIV Cohort (CHIC) Study Steering Committee. Are prior treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008; 22:349-356.
16. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
17. Le Moing V, Chene G, Carrieri MP, Basnier JM, Masquelier B, Salamon R, et al. Clinical, biologic and behavioural predictors of early immunologic and virologic response in HIV-1 infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27:372-376.
18. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54:1481-1496.
19. van Sighem A, Zhang S, Reiss P, Gras L, van der Ende M, Kroon F, et al. Immunologie, virologie, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:104-108.
20. Martinez-Cajas JL, Wainberg MA. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 2008; 68:43-72.
21. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recyling efavirenz after nevirapine failue. AIDS Res Hum Retrovir 2002; 18:835-838.
22. Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7:437-441.
23. Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila RD, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37:1147-1154.
24. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352:314-316.
25. BHIVA Writing Committee and BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2000; 1:76-101.
26. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 (Suppl 1):1-41.
27. Gazzard B, and BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005; 6 (Suppl 2):1-61.
28. The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
29. Kozal MJ, Hullsiek KH, MacArthur RD, van den Berg-Wolf M, Peng G, Xiang Y, et al. The incidence of HIV drug resistance and its impact on progression of HIV Disease among antiretroviralnaïve participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8:357-370.
30. Lampe FC, Smith CJ, Madge S, Kinloch-de Loes S, Tyrer M, Sabin CA, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:692-700.
31. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370:1923-1928.